Armata Pharmaceuticals
ARMP
24 hedge funds and large institutions have $843K invested in Armata Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $886K → $843K (-$43K)
8% less funds holding
Funds holding: 26 → 24 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$53.1K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.2K |
| 3 |
VF
Virtu Financial
New York
|
+$28.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.33K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$5.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$46K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$11K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.04K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.1K |
ARMP Hedge Fund Activity: Q3 2018 in Review
24 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2018, worth a combined $843K — down 4.9% from $886K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ARMP and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $53.1K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $46K sold.
- 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2018, down from 26 in Q2 2018.
- Funds reported $843K of Armata Pharmaceuticals stock for Q3 2018, down 4.9% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q3 2018 and 4 closed out, a net change of -2 holders.
- The largest Armata Pharmaceuticals buyer in Q3 2018 was Renaissance Technologies, an estimated $53.1K added.
- The largest Armata Pharmaceuticals seller in Q3 2018 was Acadian Asset Management, an estimated $46K sold.
Based on aggregated 13F filings for Q3 2018.